NCHR Testimony on Seroquel XR

April 8, 2009. The benefits are statistically significant in most, but not all the studies provided to the FDA. But, let’s be clear here: the patients on placebo are improving greatly in these studies – almost as much as those taking Seroquel.

Read More »

NCHR Testimony on Fablyn

September 8, 2008. Osteoporosis is a serious disease. Fortunately, there are numerous treatments available, and those options should help the FDA determine whether the risks of this drug, Fablyn, outweigh the benefits.

Read More »